The Congressional Budget Office (CBO) today released its assessment of what would happen to health insurance premiums should the administration stop paying cost-sharing reductions (CSRs).
The CBO projects the average monthly premiums would increase 20 percent next year and 25 percent by 2020.
The Senate has advanced the U.S. Food and Drug Administration’s (FDA) Reauthorization Act, which expands four separate user fee agreements on new drugs, generic drugs, medical devices, and biosimilars, and includes a provision to maximize the development of therapies for children with cancer.
PROVIDENCE – AUGUST 3 – Rhode Island is getting mixed reviews when it comes to supporting policies and passing legislation to prevent and reduce suffering and death from cancer.
The U.S. Senate fell short of the votes needed to pass legislation that would have repealed parts of the current health care law, likely resulting in millions losing health insurance and patients paying more for less coverage.
The U.S. Senate is reported to be considering a “skinny” health care repeal bill that according to earlier Congressional Budget Office estimates of similar repeal could cause 15 million Americans to lose their insurance coverage over the next ten years
A new report shows that while opportunities for coverage have improved, cancer patients still struggle with significant financial challenges in affording their treatment despite substantial reductions in out-of-pocket costs and patient protections under current law.
Any attempt to repeal the ACA without replacing it with equal or better coverage will leave our health care system in shambles. If the existing law is abolished, 32 million Americans could lose their insurance coverage in the next decade. This approach is completely unacceptable for the patients we represent.
Sacramento, CA – The voices of cancer patients, survivors and their loved ones are making a difference at the Capitol as evidenced by the critically-important cancer-fighting policies that passed the Legislature in 2016.
The House advanced legislation to reauthorize and expand the FDA's user fee programs that maintain a strong partnership between the FDA and industry, with the goal of bringing pharmaceutical drugs and devices to the market, and making them accessible to patients, as expeditiously as possible.
Sixty patients and consumers from across the country, each with their own personal health care story, gathered on Capitol Hill today to urge their senators to preserve quality health care access and coverage for millions of Americans.